U-Bisys Overview

  • Founded
  • 1996
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

U-Bisys General Information


Developer of human antibodies and antibody-derivatives for therapeutic and diagnostic purposes. The company's human antibodies and antibody-derivatives technology, MAbstract, is subtractive phage antibody-display selection technology offed by the company.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Heidelberglaan
  • 3584 Utrecht
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

U-Bisys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 30-Jun-2000 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view U-Bisys’s complete valuation and funding history, request access »

U-Bisys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
To view U-Bisys’s complete investors history, request access »